Sacituzumab tirumotecan

{
  "id": "MLC-T-ONC-016617",
  "term": "Sacituzumab tirumotecan",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of a monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated to an as of yet undisclosed toxin, with potential antineoplastic activity. Upon administration sacituzumab tirumotecan, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake, the undisclosed toxin exerts, through an as of yet not disclosed mechanism of action, its cytotoxic effect. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues; its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.",
  "synonyms": [
    "ADC SKB264",
    "anti-TROP2 antibody-drug conjugate MK-2870",
    "anti-TROP2 antibody-drug conjugate SKB264"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/sacituzumab-tirumotecan/"
}